- Home
- AMP vs ARGX Comparison
AMP vs ARGX Comparison
Compare AMP & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMP
- ARGX
- Stock Information
- Founded
- AMP 1894
- ARGX 2008
- Country
- AMP United States
- ARGX Netherlands
- Employees
- AMP N/A
- ARGX N/A
- Industry
- AMP Investment Managers
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AMP Finance
- ARGX Health Care
- Exchange
- AMP Nasdaq
- ARGX Nasdaq
- Market Cap
- AMP 44.9B
- ARGX 40.4B
- IPO Year
- AMP 2005
- ARGX 2017
- Fundamental
- Price
- AMP $492.27
- ARGX $549.65
- Analyst Decision
- AMP Hold
- ARGX Strong Buy
- Analyst Count
- AMP 6
- ARGX 20
- Target Price
- AMP $514.60
- ARGX $698.22
- AVG Volume (30 Days)
- AMP 473.1K
- ARGX 432.1K
- Earning Date
- AMP 04-24-2025
- ARGX 05-08-2025
- Dividend Yield
- AMP 1.30%
- ARGX N/A
- EPS Growth
- AMP 0.13
- ARGX N/A
- EPS
- AMP 29.43
- ARGX 15.94
- Revenue
- AMP $18,082,000,000.00
- ARGX $2,643,062,000.00
- Revenue This Year
- AMP N/A
- ARGX $60.97
- Revenue Next Year
- AMP $4.44
- ARGX $31.50
- P/E Ratio
- AMP $16.72
- ARGX $32.07
- Revenue Growth
- AMP 9.09
- ARGX 82.13
- 52 Week Low
- AMP $385.74
- ARGX $352.77
- 52 Week High
- AMP $582.05
- ARGX $678.21
- Technical
- Relative Strength Index (RSI)
- AMP 57.81
- ARGX 36.21
- Support Level
- AMP $471.76
- ARGX $529.11
- Resistance Level
- AMP $485.90
- ARGX $658.93
- Average True Range (ATR)
- AMP 12.60
- ARGX 17.55
- MACD
- AMP 3.66
- ARGX -6.04
- Stochastic Oscillator
- AMP 94.03
- ARGX 15.82
About AMP Ameriprise Financial Inc.
Ameriprise Financial is a major player in the US market for asset and wealth management, with around $1.5 trillion in total assets under management and administration at the end of 2024. With about 10,500 advisors, Ameriprise has one of the largest branded advisor networks in the industry. About 80% of the company's revenue comes from its asset and wealth management segments. Ameriprise has reduced its exposure to insurance with the sale of its auto and home insurance business in 2019 and discontinuing the sale of proprietary fixed annuities in 2020.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.